Teva to launch generic Baraclude

|By:, SA News Editor

The U.S. Court of Appeals for the Federal Circuit upholds a district court ruling invalidating Bristol-Myers Squibb's (BMY -0.2%) patent no. 5,206,244 for Baraclude (entecavir).

Teva's (TEVA -0.3%) ANDA for a generic version has received tentative approval by the FDA. The commercial launch will commence after the agency issues its final approval.

According to IMS Health, Baraclude's U.S. sales were ~$314M in the 12-month period ending in March.